Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in MS: TRACER study: STUDY

Image Source: ABDEM
Read more »

Labels: Betaseron, Plegridy, Rebif, Study

End-of-Year Task: Renewing Your DMT Prescription for 2016

By Kim Dolce—December 8, 2015

December is upon us, and besides being the holiday season, ‘tis also the season to renew our prescriptions for disease-modifying therapies and reapply for co-pay assistance.
Read more »

Labels: Avonex, Betaseron, Copaxone, Gilenya, Rebif

Development of interferon beta-neutralising antibodies in MS—a systematic review and meta-analysis: STUDY

Image Source: BETA-NEUTRALISINGANTIBODIES
Read more »

Labels: Betaseron, Rebif, Study

FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments

This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY

Read more »

Labels: Aubagio, Betaseron, Copaxone, Gilenya, Lemtrada, Rebif, Rituxan-Rituximab, TECFIDERA, Tysabri

Acceptance of the Extracare Program by Beta Interferon-Treated Patients With Multiple Sclerosis: Results of the Explore Study: STUDY

Read more »

Labels: Betaseron, Rebif, Study

Requirement Allopathic treatments for Multiple Sclerosis.

Some treatments are designed to shorten the length of flare-ups or exacerbations. Still other medications are made use of to relive symptoms of MS either short-term or long term.

Read more »

Labels: Betaseron, Rebif

Multiple sclerosis market is arguably one of the most competitive in pharma

The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in part by a handful of products (Avonex, Betaseron, Copaxone and Rebif) that are both effective, very well established and which deliver broadly comparable efficacy. In more recent years, an ´oral revolution´ has advanced the therapeutic optionality for MS patients, but simultaneously left room for further improvements.
Read more »

Labels: Betaseron, Copaxone, Rebif

Viragen Announces That OVA(TM) System Results are Published in Leading U.S. Scientific Journal Viragen, Inc.

Viragen Announces That OVA(TM) System Results are Published in Leading U.S. Scientific Journal
Viragen, Inc.
(Amex: VRA; VRA.U; VRA.WS) and its collaborative partners in the field of
avian transgenics, Roslin Institute and Oxford Biomedica Plc (LSE: OXB),
today announced that the Proceedings of the National Academy of Sciences of
the United States of America (PNAS), a leading scientific journal, has
published an article profiling the OVA(TM) System's ability to express two
therapeutic proteins in the whites of eggs of transgenic hens. The OVA(TM)
System is being developed as a novel, large-scale biomanufacturing
alternative capable of cost-effectively expressing many types of
therapeutic proteins.

The article, entitled, "Oviduct-specific expression of two therapeutic
proteins in transgenic hens," reports on the production of two protein drug
candidates: a humanized monoclonal antibody being developed by Viragen for
advanced malignant melanoma; and interferon beta-1a, which is currently
marketed under two competing brand names for the treatment of Multiple
Sclerosis (MS), as Avonex(R)* (Biogen Idec) and Rebif(R)** (Serono).

Article Summary:
Recent advances in avian transgenesis have led to the possibility of
utilizing the laying hen as a production platform for the large-scale
synthesis of pharmaceutical proteins. Ovalbumin constitutes more than half
of the protein in the white of a laid egg, and expression of the ovalbumin
gene is restricted to the tubular gland cells of the oviduct. Here we
describe the use of lentiviral vectors to deliver transgene constructs
comprising regulatory sequences from the ovalbumin gene designed to direct
synthesis of associated therapeutic proteins to the oviduct. We report the
generation of transgenic hens that synthesize functional recombinant
pharmaceutical protein in a tightly regulated tissue-specific manner,
without any evidence of transgene silencing after germ-line transmission.
MORE

Labels: Rebif

Multiple sclerosis: What you need to know about the disease

Read more »

Labels: Betaseron, Copaxone, Novantrone, Rebif, Tysabri

Treatment Plan Should Include Education, Nutrition and Appropriate Medication

There is as yet no cure for MS. Many patients do well with no therapy at all, especially since many medications have serious side effects and some carry significant risks. However, three forms of beta interferon (Avonex, Betaseron and Rebif) have now been approved by the Food and Drug Administration for treatment of relapsing-remitting MS.
Click here to read more

Labels: Betaseron, Rebif

NOVARTIS WILL PAY TO GET MSers TO USE GILENYA

Novartis will pay out-of-pocket costs for non-Medicare patients who use Gilenya! PLUS:  Novartis will also help patients navigate testing and monitoring recommended by the FDA, paying as much as $600 per patient for that expense.
Read more »

Labels: Avonex, Copaxone, Gilenya, Rebif

GOOD NEWS ON TEVA'S NEW MS TREATMENT LAQUINIMOD (NERVENTRA)

Read more »

Labels: Betaseron, Copaxone, Gilenya, Laquinimod (Nerventra), Novantrone, Rebif, Tysabri

Wow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR

Teva soaring out in front on a single product and it is no surprise that the Generics pack are waiting in the rear ready for the copaxone patents to expire starting May 2014. However Biogen are backing the most winners with a staggering $5.8 billion worth of business. 

#1 Glaterimer acetate Teva     $4.3 billion
#2 Avonex Biogen Idec           $3.0 billion
#3 Gilenya Novartis                 $1.9 billion
#4 Tysabri Biogen  Idec           $1.7 billion
#5 Betaseron Bayer                 $1.1 billion
#6 Tecfidera Biogen Idec        $0.9 billion
#7 Rebif EMD serono              $0.6 billion
#8 Ampyra Biogen Idec           $0.3 billion
#9 Aubagio Sanofi                   $0.2 billion
#10 Extavia Novartis               $0.2 billion
Read more »

Labels: 20 Best Stories & Studies, Ampyra, Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Rebif, TECFIDERA, Tysabri

IMPORTANT UPDATE: "American specialists should also be aware of this worrisome but rare adverse effect, said MS expert Aaron Miller, MD, Icahn Mount Sinai School of Medicine, NYC"

Aaron Miller, MD, Icahn Mount Sinai School of Medicine New York City

Cases of unexpected, serious, and even fatal thrombotic microangiopathy (TMA) linked to use of a new serum-free formulation of interferon beta (Rebif) have emerged in patients with MS
In a Letter to the Editor published in the March 27 issue of the New England Journal of Medicine, David Hunt, PhD, from Edinburgh University, and colleagues reported on 4 such cases that were diagnosed in South Scotland during an 18-month period. Regulatory authorities in the United Kingdom received 6 additional spontaneous reports of disorders related to TMA and the same formulation of interferon beta, which was introduced in Europe in September 2007, the letter notes. 

The authors call for specialists to be on the lookout for signals of this rare adverse effect of interferon beta in their patients with MS.

Read more »

Labels: Betaseron, Rebif

Multiple Sclerosis and Pregnancy: Current Considerations

Read more »

Labels: Betaseron, Copaxone, Gilenya, Pregnancy, Rebif, Tysabri

HOW MS MEDICATIONS DIFFER FROM EACH OTHER

Read more »

Labels: Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, Rebif, TECFIDERA, Tysabri

Synthetic Biologics Announces Issuance of U.S. Patent patents for MS and other autoimmune diseases covering the uses of its oral estriol candidate, Trimesta

Read more »

Labels: Betaseron, Copaxone, Extavia, For Doctors, Gilenya, Rebif

THE AMAZING DOCTOR WHO WAS PART OF A TEAM WHO HELPED INVENT COPAXONE & REBIF & IS NOW FOCUSING ON STEM CELLS AT 75

Read more »

Labels: 20 Best Stories & Studies, Copaxone, Rebif

FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments

This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY

Read more »

Labels: Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Lemtrada, Rebif, Rituxan-Rituximab, TECFIDERA, Tysabri

15 STUDIES IN FRIDAY'S NEWS

 PLUS: 1590 new Studies we posted from 11/1 to Thursday 2/12 Start at the Bottom!

The NBSS, developed specifically to assess the symptoms and consequences associated with neurogenic bladder dysfunction, has appropriate psychometric properties. Depending on the measurement need, individual domains may be selected, or it can be used as a comprehensive score.

Read Study at Pubmed.gov

The fraction of intrathecally-produced VZV-specific IgG of the total intrathecally produced IgG discriminates between patients with VZV reactivation and MS. Our results provide further evidence that intrathecally-produced VZV antibodies are part of the polyspecific immune response in patients with MS.

Read study at Pubmed.gov

 In addition to autoantigens implicated in thyroid autoimmunity, fibrocytes and derivative fibroblasts express multiple autoantigens associated with T1DM. This expression results from active gene promoters and abundant steady-state mRNA encoding ICA69 and IA-2. These latest findings demonstrate that fibrocytes express antigens relevant to multiple forms of endocrine autoimmunity. They suggest the potential for these cells playing a direct role in immune reactivity directed at the thyroid and pancreatic islets.

Read Study at Pubmed.gov

MMPs can also enhance the cleavage of myelin basic protein (MBP) and the demyelination process. Regarding the growing data on the roles of MMPs and their tissue inhibitors (TIMPs) in the pathogenesis of MS, this review discusses the role of different types of MMPs, including MMP-2, -3, -7, -9, -12 and -25, in the immunopathogenesis and treatment of MS.

Read Study at Pubmed.gov

In a real-world setting, patients with MS who switched from IFNs to fingolimod were significantly less likely to experience relapses than those who switched to GA.
Read Study Pubmed.gov

Read more »

Labels: 500 BEST PML STORIES & STUDIES, Aubagio, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, PML (Progressive Multifocal Leukoencephalopathy), Rebif, Sativex, TECFIDERA, Tysabri